

ORIGINAL RESEARCH

IMAGING

Obstructive Coronary Artery Disease Improved Prediction by the COME-CCT Pretest Probability Calculator With Cardiac CT



Viktoria Wieske, MD,^{a,*} Mario Walther, MD,^{b,*} Mahmoud Mohamed, PhD,^{a,*} Benjamin Weickert, MD,^a Simon Andrzejewski, MD,^a Benjamin Dubourg, MD,^c Daniele Andreini, MD,^d Gianluca Pontone, PhD,^d Hatem Alkadhi, MD,^e Jörg Hausleiter, MD,^f Mario J. Garcia, MD,^g Sebastian Leschka, MD,^h Willem B. Meijboom, MD,ⁱ Elke Zimmermann, MD,^a Bernhard Gerber, MD,^j U Joseph Schoepf, MD,^k Abbas A. Shabestari, MD,^l Bjarne L. Nørgaard, PhD,^m Matthijs FL. Meijs, PhD,ⁿ Akira Sato, MD,^o Kristian A. Øvrehus, PhD,^p Axel CP. Diederichsen, PhD,^p Shona M. Jenkins, MD,^q Juhani Knuuti, MD,^r Ashraf Hamdan, MD,^s Bjørn A. Halvorsen, MD,^t Vladimir Mendoza Rodriguez, PhD,^u Carlos Rochitte, MD,^v Johannes Rixe, MD,^w Yung-Liang Wan, MD,^x Christoph Langer, MD,^y Nuno Bettencourt, PhD,^z Eugenio Martuscelli, MD,^{aa} Said Ghostine, MD,^{ab} Ronny R. Buechel, MD,^{ac} Konstantin Nikolaou, MD,^{ad} Hans Mickley, MD,^p Lin Yang, MD,^{ae} Zhaqoi Zhang, MD,^{ae} Marcus Y. Chen, MD,^{af} David A. Halon, MD,^{ag} Matthias Rief, MD,^a Kai Sun, MD,^{ah} Hiroyuki Niinuma, MD,^{ai} Roy P. Marcus, MD,^{aj} Simone Muraglia, MD,^{ak} Réda Jakamy, MD,^{al} Benjamin JW. Chow, MD,^{am} Philipp A. Kaufmann, MD,^{an} Bernhard A. Herzog, MD,^{ao} Jean-Claude Tardif, MD,^{ap} Cesar Nomura, MD,^{aq} Klaus F. Kofoed, PhD,^{ar} Jean-Pierre Laissy, MD,^{as} Armin Arbab-Zadeh, MD,^{at} Kakuya Kitagawa, MD,^{au} Roger Laham, MD,^{av} Masahiro Jinzaki, MD,^{aw} John Hoe, MD,^{ax} Frank J. Rybicki, MD,^{ay} Arthur Scholte, MD,^{az} Narinder Paul, MD,^{ba} Swee Yaw Tan, MD,^{bb} Kunihiro Yoshioka, MD,^{bc} Robert Roehle, MSc,^a Georg M. Schuetz, MD,^a Michael Laule, MD,^{bd} David E. Newby, MD,^{be} Stephan Achenbach, MD,^{bf} Matthew Budoff, MD,^{bg} Robert Haase, MD,^a Jonathan D. Dodd, MD,^{bh,†} Marc Dewey, PhD,^{a,bi,bj,†} Peter Schlattmann, PhD,^{bk,†} the COME-CCT Consortium

ABSTRACT

BACKGROUND Combining pretest probability (PTP) with computed tomography angiography (CTA) for diagnosing obstructive coronary artery disease (CAD) has not yet been determined.

OBJECTIVES The purpose of this study was to evaluate the accuracy of PTP calculation alone and with CTA for diagnosing CAD.

METHODS A total of 65 prospective diagnostic accuracy studies of patients clinically referred to invasive coronary angiography with stable chest pain were included in this international collaborative individual patient data Collaborative Meta-Analysis of Cardiac CT (COME-CCT) meta-analysis. Mixed-effects logistic regression with a data set-specific random intercept for clustering was applied to 4 models: the traditional Diamond-Forrester models, a PTP model based on the COME-CCT data (termed COME-CCT-PTP calculator), a CTA alone model, and a combined COME-CCT-PTP with CTA model.

RESULTS Individual patient data from 5,332 patients with clinically indicated invasive coronary angiography from 22 countries were included. The COME-CCT-PTP calculator was more accurate than the original Diamond-Forrester model (AUC: 0.68; 95% CI: 0.66-0.69 vs 0.63; 95% CI: 0.62-0.65). The COME-CCT-PTP with CTA model significantly improved accuracy compared with either model alone (AUC: 0.86; 95% CI: 0.85-0.87 vs 0.81; 95% CI: 0.80-0.82). The improved prediction was consistent in decision curve analysis with an increased net benefit for all chest pain subtypes and was almost equally seen in patients with typical or atypical angina (0.85; 95% CI: 0.84-0.86) and nonanginal or other chest discomfort (0.88; 95% CI: 0.86-0.89).

ABBREVIATIONS
AND ACRONYMS

AUC = area under the curve
CAD = coronary artery disease
CTA = computed tomography angiography
ESC = European Society of Cardiology
ICA = invasive coronary angiography
PTP = pretest probability

CONCLUSIONS Combining the COME-CCT-PTP calculator with CTA provides more accurate prediction than the PTP or CTA alone for the diagnosis of obstructive CAD, for all chest pain subtypes.

(JACC Adv. 2025;4:102014) © 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

The prevalence of obstructive coronary artery disease (CAD) has decreased in men but increased in women, while disability-adjusted life years related to CAD are projected to increase to 2,275.9 worldwide

by 2022.¹ Stable chest pain is a common initial presentation of CAD^{2,3} and associated with the same increase in coronary mortality in women and men.^{4,5} Invasive coronary angiography (ICA) is the reference standard for the final diagnosis of obstructive CAD in

From the ^aInstitute of Biometry and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, Berlin, Germany; ^bDepartment of Fundamental Sciences, Jena University of Applied Sciences, Jena, Germany; ^cCardiac Imaging Unit, Department of Radiology, Rouen University Hospital, Rouen, France; ^dCentro Cardiologico Monzino, IRCCS, Milan, Italy; ^eInstitute of Diagnostic and Interventional Radiology University Hospital Zurich, Zurich, Switzerland; ^fMaximilians-University of Munich, Munich, Germany; ^gDepartment of Cardiology, Montefiore, University Hospital for the Albert Einstein College of Medicine, New York, New York, USA; ^hDepartment of Radiology, St Gallen, Switzerland; ⁱDepartment of Cardiology, Erasmus University Medical Centre, Rotterdam, Netherlands; ^jDepartment of Cardiology, Clinique Universitaire St Luc, Institut de Recherche Clinique et Expérimentale, Brussels, Belgium; ^kDepartment of Radiology and Radiological Science, Medical University of South Carolina, Charleston, South Carolina, USA; ^lModarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ^mDepartment of Cardiology, Aarhus University Hospital, Aarhus, Denmark; ⁿDepartment of Cardiology, University Medical Centre Utrecht, Utrecht, Netherlands; ^oCardiovascular Division, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan; ^pDepartment of Cardiology, Odense University Hospital, Odense, Denmark; ^qGlasgow Royal Infirmary and Stobhill Hospital, Glasgow, United Kingdom; ^rTurku University Hospital and University of Turku, Turku, Finland; ^sCardiology Department, Rabin Medical Center, Petah Tikva, and Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel; ^tDepartment of Cardiology, Ostfold Hospital Trust, Grålum, Norway; ^uDepartment of Cardiology, Woodlands Limited Hospital; Georgetown, Guyana; ^vHeart Institute, InCor, University of São Paulo Medical School, São Paulo, Brazil; ^wDepartment of Cardiology, Kerckhoff Heart Centre, Bad Nauheim, Germany; ^xMedical Imaging and Radiological Sciences, College of Medicine, Chang Gung University, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; ^yKardiologisch-Angiologische Praxis, Herzzentrum Bremen, Bremen, Germany; ^zDepartment of Cardiology, Centro Hospitalar de Vila Nova de Gaia, Vila Nova de Gaia, Portugal; ^{aa}Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy; ^{ab}Department of Cardiology, Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France; ^{ac}Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland; ^{ad}Department of Diagnostic and Interventional Radiology, University Hospital of Tübingen, Tübingen, Germany; ^{ae}Department of Radiology, Beijing Anzhen Hospital, Beijing, China; ^{af}National Heart and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA; ^{ag}Cardiovascular Clinical Research Unit, Lady Davis Carmel Medical Center, Haifa, Israel; ^{ah}Department of Radiology, Baotou Central Hospital, Inner Mongolia Province, China; ^{ai}St Luke's International Hospital, Tokyo, Japan; ^{aj}Cantonal Hospital of Lucerne, Lucerne, Switzerland; ^{ak}Department of Cardiology, S Chiara Hospital, Trento, Italy; ^{al}Department of Cardiology, University Hospital Pitié-Salpêtrière, Paris, France; ^{am}University of Ottawa Heart Institute, Ottawa, Ontario, Canada; ^{an}Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland; ^{ao}HeartClinic Lucerne, Lucerne, Switzerland; ^{ap}Montreal Heart Institute, Université de Montréal, Montréal, Canada; ^{aq}Albert Einstein Hospital, São Paulo, Brazil; ^{ar}The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; ^{as}Department of Radiology, Gonesse Hospital Center, Gonesse, France; ^{at}Division of Cardiology, Johns Hopkins Hospital, Johns Hopkins University, Baltimore, Maryland, USA; ^{au}Mie University Hospital, Tsu, Japan; ^{av}BIDMC/Harvard Medical School, Department of Cardiology, Beth Israel Deaconess Medical Center, Harvard University, Boston, Massachusetts, USA; ^{aw}Department of Radiology, Keio University Hospital, Tokyo, Japan; ^{ax}Department of Radiology, Mount Elizabeth Hospital, Singapore, Singapore; ^{ay}Department of Radiology, University of Cincinnati, Cincinnati, Ohio, USA; ^{az}Department of Cardiology, Leiden University Medical Centre, Leiden, Netherlands; ^{ba}Department of Medical Imaging, Western University, London, Ontario, Canada; ^{bb}National Heart Centre, Singapore, Singapore; ^{bc}Iwate Medical University, Morioka, Japan; ^{bd}Department of Cardiology, Charité - Universitätsmedizin Berlin, Berlin, Germany; ^{be}British Heart Foundation Centre of Research Excellence, University of Edinburgh, Edinburgh, United Kingdom; ^{bf}Department of Cardiology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; ^{bg}Lundquist Institute, Harbor-UCLA Medical Center, Torrance, California, USA; ^{bh}Department of Radiology, St. Vincent's University Hospital and School of Medicine, University College Dublin, Dublin, Ireland; ^{bi}Berlin Institute of Health, Berlin, Germany; ^{bj}DZHK (German Centre for Cardiovascular Research), Berlin, Germany; and the ^{bk}Institute of Medical Statistics, Computer Sciences and Data Science, University Hospital of Friedrich Schiller University Jena, Jena, Germany. *These authors contributed equally as first authors. †These authors contributed equally as last authors.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).

Manuscript received February 15, 2025; revised manuscript received June 20, 2025, accepted June 23, 2025.

patients with stable chest pain but decision-making about referral to ICA can be challenging.⁶ To facilitate appropriate referral to ICA in stable chest pain patients, American⁷ and European guidelines⁸ recommend pragmatic clinical prediction models for estimation of the probability of obstructive CAD. The American guideline recommends the updated contemporary models such as Juarez-Orozco et al⁹ while European guidelines recommend using age, sex, symptoms, and risk factors.⁸ The discriminative ability of these diagnostic prediction models has not been tested in large contemporary cohorts of patients clinically referred for ICA because of stable chest pain with suspected obstructive CAD.

We initiated the COME-CCT (Collaborative Meta-Analysis of Cardiac CT) Consortium to combine individual patient data from current diagnostic accuracy studies in which ICA served as the diagnostic reference standard and computed tomography angiography (CTA) was the index test in patients with stable chest pain suggestive of CAD. This allowed the calculation of a pretest probability (PTP) calculator, which we have termed the “COME-CCT-PTP calculator.”¹⁰ In this analysis, we investigated the discriminative ability of traditional PTP models such as the Diamond Forrester models compared with the COME-CCT-PTP calculator to identify patients with obstructive CAD. We also evaluated whether adding CTA results to the COME-CCT-PTP calculator resulted in a better prediction of obstructive CAD on ICA in patients with stable chest pain.

METHODS

The COME-CCT Consortium conducted an individual patient data meta-analysis of diagnostic accuracy data sets published between 2004 and 2014 that included patients with stable chest pain and suspected CAD in whom CTA was the index test and clinically indicated ICA served as the reference standard. The detailed protocol of the COME-CCT Consortium including the eligibility criteria, data collection, and harmonization and search strategy has been previously published^{11,12} and was registered in the PROSPERO Database for Systematic Reviews (CRD42012002780). For all retrieved studies, CTA results were blinded and thus did not influence the decision to perform ICA, avoiding verification bias. The ICA results were blinded to authors assessing clinical predictors and to CTA readers. The results from the international individual patient data meta-analysis were used to calculate a PTP calculator, termed the “COME-CCT-PTP calculator.” Reporting of our study follows the TRIPOD

(Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis) statement¹³ (see the TRIPOD checklist in the [Supplemental Appendix](#)) and the suggestions of Debray et al regarding diagnostic prediction models using individual participant data meta-analysis.¹⁴ Quality assessment of published articles was performed using the QUADAS (quality assessment tool for diagnostic accuracy studies) and the STARD (Standards for Reporting of Diagnostic Accuracy) checklist, and results were recently published on the study-level.^{15,16} We used the methodology described by Wasson and Sox in developing the COME-CCT diagnostic prediction models.¹⁷ This meta-analysis did not require Institutional Board Review as it involved the secondary analysis of publicly available, deidentified data.

CAD PREDICTION MODELS. Three CAD prediction models were built by using a mixed effects logistic regression model based on the COME-CCT data with a data set-specific random intercept to account for clustering.¹⁸ For the COME-CCT-PTP calculator, typical angina was considered when the following 3 criteria were fulfilled: retrosternal chest discomfort, precipitation by exertion, and prompt relief (within 30 s–10 min) by rest or nitroglycerin.¹⁹ Patients who met 2, one, or none of these 3 criteria were classified as having atypical angina, nonanginal chest discomfort, and other chest discomfort, respectively. The category “other chest discomfort” was used as recommended²⁰ since these patients were not asymptomatic but had chest pain not fulfilling any of the 3 criteria. These criteria are also used in the Diamond-Forrester prediction models recommended in previous European guidelines.²¹ To assess whether CTA alone can be used as an accurate predictor of CAD, we performed a second logistic regression model incorporating CTA alone.²² Finally, to assess whether a combination of the COME-CCT-PTP calculator combined with CTA results was a better predictor than either model alone, we performed a third logistic regression model incorporating CTA as an additional covariate.

STATISTICAL ANALYSIS. Individual patient data were analyzed using a mixed effects logistic regression model with a data set-specific random intercept to take clustering within studies into account.¹⁸ No imputation methods were used and only patients with complete information required for pragmatic prediction models were included. The binary outcome “obstructive CAD” was defined in all retrieved studies as at least one $\geq 50\%$ diameter stenosis by ICA. The analysis was performed including

nondiagnostic CTA results in the model using 2-by-3 tables.²³ For nondiagnostic CTA results, we assumed a worst-case scenario, that is, for an ICA negative result, we defined a corresponding nondiagnostic CTA result to be CTA positive, and an ICA positive result with a nondiagnostic CTA was defined as CTA negative. All covariates (age, sex, chest pain type, and CTA) in the regression models were included as main effects. No interaction terms were used. The incremental gain from using CTA results in estimating CAD probability combined with the COME-CCT-PTP calculator was evaluated by reduction of the Bayesian information criterion. Disease probabilities were predicted by averaging over the random-effects distribution.²⁴ A sensitivity analysis of the predictions was performed using an average intercept applied over all studies.²⁵ Potential publication bias was assessed as described previously.¹² Overall performance of the models for predicting CAD probability was evaluated by the scaled Brier score, which measures the accuracy of probabilistic prediction.²⁶ A perfect model results in a Brier score of zero or a scaled Brier score of one. Discriminative ability of the models, that is, the ability of discriminating patients with obstructive CAD from those without, was quantified using the area under the receiver-operating characteristic curve (AUC) with 95% CIs.²⁷ Calibration as the extent of disagreement and bias with respect to observed and predicted outcomes was investigated graphically based on calibration plots. We also evaluated all 3 prediction models in terms of their benefit in clinical practice using decision curve analysis.²⁸

Internal model validation for the models with and without CTA was based on 250 bootstrap samples of the original data,²⁹ using AUC, scaled Brier score, accuracy, and the discrimination slope,³⁰ which was calculated as the absolute difference in average predictions for those with and without CAD. Furthermore, the COME-CCT-PTP calculator was compared with the original Diamond-Forrester³¹ and updated Diamond-Forrester prediction models³² using the same 3 clinical variables and the published coefficients of the respective models. Comparison with the original Diamond-Forrester model included 4,099 patients aged 30 to <70 years while the updated Diamond-Forrester model included all age groups but included nonanginal or other chest discomfort. We applied internal-external cross-validation as described,²⁵ where the ratio of expected and observed events and also the calibration slope were considered. The average calibration slope was calculated using a random-effects meta-analytical method with inverse variance as weights.³³ All


computations were performed with the statistical software R³⁴ using lme4 package³⁵ to apply generalized linear mixed models and PredictABEL package³⁶ for evaluating model calibration and discrimination and meta³⁷ for investigating averaged calibration slopes. Decision curve analysis was run using the dca-function of R.

RESULTS

A total of 5,332 stable chest pain patients with clinically indicated ICA from 22 countries were included, see **Figure 1**. Number of patients with (2,573) and without obstructive CAD (2,759) was almost equal with a CAD prevalence of 48.3%. Clinical and technical characteristics of the studies are shown in **Table 1**, and general study characteristics can be found in **Supplemental Table 1**. Participant characteristics for each study, further study characteristics, and technical characteristics of imaging testing can be found in the COME-CCT main analysis publication.¹² The median age was 61 years, about 2-thirds were male, and the majority of patients had either typical or atypical angina.

COME-CCT-PTP CALCULATOR ALONE. The COME-CCT-PTP calculator improved discrimination of patients with suspected CAD with an AUC of 0.68 (95% CI: 0.66-0.69) compared with the original Diamond-Forrester prediction model (AUC = 0.63 [95% CI: 0.62-0.65]) (**Figure 2A**) but not when compared with the updated Diamond-Forrester prediction model (AUC = 0.68 [95% CI: 0.66-0.69]). **Table 2** shows the COME-CCT-PTP calculator results according to age, sex, and chest pain type combined with CTA results. Data set-specific results are shown in **Supplemental Table 3**. Internal validation of the COME-CCT-PTP calculator showed minimal optimism bias, indicating valid estimates of performance (**Supplemental Table 4**). Internal-external cross-validation showed a median AUC of 0.72 (IQR: 0.62-0.80) (**Supplemental Table 5**). The meta-analytic average calibration slope was 1.13 (95% CI: 0.94-1.32) and a median ratio of expected/observed results of 1.05 (IQR: 0.81-1.31) (**Supplemental Table 5**). **Supplemental Figure 1** presents a graphic analysis of calibration of the pragmatic clinical prediction model. For the average intercept model in the sensitivity analysis, we obtained an average calibration slope of 1.00 (95% CI: 0.83-1.16) (**Supplemental Table 6**).

CTA ALONE. Using CTA alone resulted in an AUC to predict CAD of 0.81 (95% CI: 0.80-0.82) (**Figure 2B**). Data set-specific results are shown in



Supplemental Table 7. The CTA alone model showed improved stratification of patients with and without obstructive CAD compared to the COME-CCT-PTP calculator (**Supplemental Figures 2 and 3**). Internal validation of prediction of the CTA alone model showed minimal optimism bias indicating valid estimates of the performance (**Supplemental Table 4**). Decision curve analysis regarding net benefit of the CTA alone model showed improved discrimination compared with the COME-CCT-PTP calculator (**Figure 3**). Internal-external cross-validation showed a median AUC of 0.86 (IQR: 0.79-0.93) (**Supplemental Table 8**). We found a meta-analytic average calibration slope of 1.13 (95% CI: 0.94-1.32). For the average intercept model in the sensitivity analysis, we obtained an average calibration slope of 1.00 (95% CI: 0.83-1.16) (**Supplemental Table 6**).

COME-CCT-PTP CALCULATOR WITH CTA. Combining CTA with the COME-CCT-PTP calculator improved CAD probability prediction compared with either alone, and resulted in a good discriminative ability with an AUC of 0.86 (95% CI: 0.85-0.87) (**Figure 2B**) (**Table 3**). The heterogeneity measured by the variance component estimate was reduced from 0.667 to 0.377 when CTA was combined with the COME-CCT-PTP calculator (**Table 3**), indicating 43.5% of the variability between sites was explained by CTA. Data set-specific results are shown in **Supplemental Table 10**.

The addition of CTA to the COME-CCT-PTP calculator improved stratification of patients with and without obstructive CAD (**Supplemental Figures 2 and 3**). Data set-specific results of the AUC (**Supplemental Table 10**) showed a substantial decrease in heterogeneity between studies when CTA was combined with the COME-CCT-PTP calculator model (**Supplemental Figure 4**). Internal validation of prediction including CTA showed minimal optimism bias indicating valid estimates of performance (**Supplemental Table 4**). Decision curve analysis regarding net benefit of including CTA in prediction showed markedly improved discrimination compared with the COME-CCT-PTP calculator alone (**Figure 3**). Internal-external cross-validation showed a median AUC of 0.91 (IQR: 0.84-0.95) (**Supplemental Table 11**). There was an average calibration slope of 1.28 (95% CI: 1.09-1.47) and a median ratio of expected/observed results of 1.01 (IQR: 0.90-1.19) (**Supplemental Table 11**). For the average intercept model in the sensitivity analysis, there was an average calibration slope of 1.19 (95% CI: 1.02-1.37) (**Supplemental Table 12**). **Supplemental Figure 5** presents a graphic analysis of calibration of the pragmatic clinical prediction model with CTA.


SUBGROUP ANALYSES. The discriminative ability of the COME-CCT-PTP calculator decreased with less typical chest pain (typical or atypical angina

TABLE 1 Participant Characteristics

	Obstructive CAD (n = 2,573)	No CAD (n = 2,759)	Total (n = 5,332)
Age (in y), median (IQR)	63 (56-70)	60 (53-67)	61 (54-69)
Male	1947 (75.7%)	1,526 (55.3%)	3,473 (65.1%)
Chest pain symptoms			
Typical angina	1,199 (46.6%)	768 (27.8%)	1967 (36.9%)
Atypical angina	641 (24.9%)	951 (34.5%)	1,592 (29.9%)
Nonanginal chest discomfort	324 (12.6%)	472 (17.1%)	796 (14.9%)
Other chest discomfort	409 (15.9%)	568 (20.6%)	977 (18.3%)
Risk factor distribution, n/N (%)			
Arterial hypertension	1,442/2,374 (60.7%)	1,207/2,512 (48.1%)	2,649/4,886 (54.2%)
Diabetes mellitus	559/2,379 (23.5%)	347/2,517 (13.8%)	906/4,896 (18.5%)
Hyperlipidemia	1,322/2,242 (59.0%)	1,079/2,326 (46.4%)	2,401/4,568 (52.6%)
Smoker	697/2,378 (29.3%)	592/2,519 (23.5%)	1,289/4,897 (26.3%)
Former smoker	455/1793 (25.4%)	442/1949 (22.7%)	897/3,742 (24.0%)
Positive family history	911/2,212 (41.2%)	889/2,346 (37.9%)	1800/4,558 (39.5%)
CT detector rows, n/N (%)			
16	583/2,504 (23.3%)	674/2,720 (24.8%)	1,257/5,224 (24.1%)
23	368/2,504 (14.7%)	381/2,720 (14.0%)	749/5,224 (14.3%)
40	77/2,504 (3.1%)	145/2,720 (5.3%)	222/5,224 (4.3%)
64	1,219/2,504 (48.7%)	1,219/2,720 (44.8%)	2,438/5,224 (46.7%)
128	100/2,504 (4.0%)	127/2,720 (4.7%)	227/5,224 (4.4%)
320	157/2,504 (6.3%)	174/2,720 (6.4%)	331/5,224 (6.3%)
CTA showing obstructive CAD ^b	2,251 (87.5%)	728 (26.4%)	2,979 (55.9%)
Information on effective dose	1935 (75.2%)	2073 (75.1%)	4,008 (75.2%)
Effective dose (in mSv), mean (SD)	13.27 (6.9) (n = 1935)	13.5 (7.8) (n = 2073)	13.39 (7.4) (n = 4,008)

Figures are numbers (percentage) of patients unless stated otherwise^a. ^aAdditional study characteristics can be found in [Supplemental Table 1](#). ^bObstructive CAD was defined as ≥50% coronary diameter stenosis by CTA and ICA.

CAD = coronary artery disease; CTA = computed tomography angiography; CT = computed tomography.

FIGURE 2 Discriminative Ability of Prediction Models

Panel (A) shows the receiver-operating characteristic (ROC) curves of the clinical probability prediction (PTP) models. The COME-CCT-PTP calculator (red) and updated Diamond-Forrester model (gray) resulted in significantly improved discrimination compared to the original Diamond-Forrester model (black). Panel (B) shows the significantly improved discriminative ability using the combination of the COME-CCT-PTP calculator with CTA (solid blue) compared to CTA alone (dashed blue). COME-CCT = Collaborative Meta-Analysis of Cardiac CT; DICAD = updated Diamond-Forrester model; other abbreviation as in [Figure 1](#).

TABLE 2 COME-CCT-PTP Calculator Results According to Age, Sex, Classification of Chest Pain Type, and Stratified by CTA Results Showing Obstructive (+) and Nonobstructive CAD (–) Based on the Combined Prediction Model and CTA


Age, y	Typical Angina		Atypical Angina		Nonanginal Chest Discomfort		Other Chest Discomfort	
	Women	Men	Women	Men	Women	Men	Women	Men
20	21	39	9	19	7	17	7	15
CT+/-	50/6	69/13	26/2	44/5	25/2	43/4	22/2	39/4
25	24	43	10	22	9	19	8	17
CT+/-	54/7	72/15	29/2	47/5	28/2	46/5	25/2	43/4
30	27	47	12	25	10	22	9	20
CT+/-	57/8	75/16	31/3	51/6	31/3	50/6	28/2	46/5
35	30	51	14	28	12	25	11	23
CT+/-	60/9	77/18	34/3	54/7	34/3	53/7	31/3	49/6
40	34	55	16	31	14	28	12	26
CT+/-	64/10	80/21	38/4	57/8	37/3	56/8	34/3	53/7
45	37	59	18	35	16	31	14	29
CT+/-	67/12	82/23	41/4	61/9	40/4	60/9	37/3	56/8
50	41	62	21	38	18	34	16	32
CT+/-	70/13	84/26	44/5	64/10	43/5	63/10	40/4	60/9
55	45	66	23	42	20	38	19	36
CT+/-	73/15	86/28	48/5	67/12	47/5	66/11	43/5	63/10
60	49	69	26	46	23	42	21	39
CT+/-	75/17	87/31	51/6	70/13	50/6	69/13	47/5	66/11
65	53	73	30	50	26	46	24	43
CT+/-	78/19	89/34	55/7	73/15	54/7	72/15	50/6	69/13
70	57	76	33	54	29	50	27	47
CT+/-	80/21	90/38	58/8	76/17	57/8	75/16	54/7	72/15
75	60	79	37	58	33	54	31	51
CT+/-	82/24	91/41	61/9	78/19	60/9	77/19	57/8	75/16
80	64	81	40	61	36	57	34	55
CT+/-	84/26	93/44	65/11	80/21	64/10	80/21	60/9	77/18
85	68	84	44	65	40	61	38	59
CT+/-	86/29	93/48	68/12	83/24	67/12	82/23	64/10	80/21
90	71	86	48	69	44	65	41	63
CT+/-	88/32	94/51	71/14	84/26	70/13	84/26	67/12	82/23
95	74	88	52	72	48	68	45	66
CT+/-	89/35	95/54	73/15	86/29	73/15	86/28	70/13	84/26
100	77	89	56	75	52	72	49	70
CT+/-	91/38	96/58	76/17	88/32	75/17	87/31	73/15	86/28
105	80	91	60	78	56	75	53	73
CT+/-	92/41	96/61	79/20	89/35	78/19	89/34	75/17	87/31

Numbers are percentages unless otherwise stated. Typical angina defined as retrosternal chest discomfort, precipitation by exertion, and prompt relief (within 30 s-10 min) by rest or nitroglycerin.¹⁹ Patients who met 2, 1, or 0 of these 3 criteria were classified as having atypical angina, nonanginal chest discomfort, and other chest discomfort, respectively. COME-CCT = Collaborative Meta-Analysis of Cardiac CT; PTP = pretest probability; other abbreviations as in Table 1.

(0.70; 95% CI: 0.68-0.71) vs nonanginal or other chest discomfort (0.63; 95% CI: 0.60-0.65) (**Central Illustration**). The improved prediction of CAD by combining CTA with the COME-CCT-PTP calculator prediction model was consistent in decision curve analysis with an increased net benefit for all chest pain types and was almost equally seen in patients with typical or atypical angina. Similar improvement was seen in terms of AUC in patients with typical or atypical angina (0.85; 95% CI: 0.84-0.86) and nonanginal or other chest discomfort (0.88; 95% CI: 0.86-0.89) (**Central Illustration**). Results stratified by symptoms were similar in the sensitivity analysis (**Supplemental Tables 13 to 18**). For the prediction model including CTA alone, the discriminative ability

in the subgroups was decreased compared to the combined model: for patients with typical or atypical angina (0.79; 95% CI: 0.77-0.80) vs nonanginal or other chest discomfort (0.85; 95% CI: 0.83-0.86).

Similar analysis for other subgroups including sex, age, and CAD prevalence showed similar results. For sex, the COME-CCT-PTP calculator with CTA improved discrimination (AUC = 0.85; 0.84-0.86) compared with the CTA alone model (AUC = 0.80; 0.79-0.81) and COME-CCT-PTP calculator alone (AUC = 0.65; 0.63-0.66) for both sexes (**Supplemental Figure 6**). For age, the COME-CCT-PTP calculator with CTA improved discrimination (AUC = 0.86; 0.84-0.87) compared with the CTA alone model (AUC = 0.80; 0.79-0.81) and the COME-CCT-PTP

FIGURE 3 Decision Curves of the COME-CCT-PTP Calculator Alone, CTA Alone, and Combined COME-CCT-PTP Calculator and CTA

The figure shows the net benefit of the COME-CCT-PTP calculator alone (red), combined with CTA (blue) and CTA alone (dashed blue) as a function of threshold probability. Patients are classified as test-positive (diagnosed with obstructive CAD) or test-negative (no CAD) based on their CAD probability. The net benefit based on the CTA alone model performed better than the COME-CCT-PTP calculator, and further improved by the combination. The black line represents the net benefit of considering all patients as having no CAD; the gray line represents the net benefit of considering all patients to have obstructive CAD. The intersection of the black with the gray line indicates the prevalence of obstructive CAD (48.3%) in our patient sample. PTP = pretest probability; other abbreviations as in [Figures 1 and 2](#).

calculator alone (AUC = 0.67; 0.66-0.68) ([Supplemental Figure 7](#)). The COME-CCT-PTP calculator with CTA performed slightly better in patients < 50 years of age. For CAD prevalence, the COME-CCT-PTP calculator alone, CTA alone, and combined all performed better in patients with low CAD prevalence compared to the higher CAD prevalence ([Supplemental Figure 8](#)).

DISCUSSION

In comparison to ICA as the reference standard for CAD, our analysis showed pragmatic clinical prediction models to have limited discriminative ability in patients with stable chest pain suggestive of CAD. Combining clinical probability calculators with CTA improved discriminative ability compared to either alone, showing added value especially for patients with typical and atypical angina pectoris with improved patient stratification. The principal findings are immediately relevant for the diagnostic management of patients presenting with stable chest pain

because clinically predicting whether or not a patient has obstructive CAD is pivotal but challenging.⁶

The Cochrane individual patient data meta-analysis methods group showed that individual patient data are being underutilized to facilitate guideline drafting and application.³⁸ The current analysis has great clinical potential to improve existing guidelines in patients with stable chest pain suggestive of obstructive CAD^{7,22} by ensuring that routine patient care is based on the most reliable evidence available.³⁸ Whether pragmatic clinical prediction of PTP, as recommended by the U.S. American and European guidelines, should always precede CTA or whether patients with stable typical or atypical angina should undergo direct CTA, as recommended in the updated National Institute for Health and Care Excellence clinical guideline 95, is an important question. We believe our data show that the combination of PTP and CTA provides the greatest clinical value.

While updated guidelines use PTP models provide much lower predicted rates of obstructive CAD, we were unable to use the updated European Society of Cardiology (ESC) 2019 PTP calculator²² as it includes dyspnea as a variable in the score and most retrieved papers did not provide a record of these data on an individual patient data level. We wanted a fair comparison to the Genders PTP model^{32,39} in similar cohorts with similar disease prevalences so that is why we included the Diamond-Forrester PTP models. Furthermore, the COME CCT individual patient data were collected from trials between 2004 and 2014 with an obstructive CAD prevalence of 48.3%, the closest CAD prevalence to the Diamond-Forrester and the updated Diamond-Forrester prediction models used in the 2013 ESC guidelines.²¹ The 2019 ESC PTP calculations were updated due to the decrease in obstructive CAD prevalence. The 2024 ESC PTP included coronary artery calcium score which does not provide an assessment of noncalcified plaque (a major predictor of major adverse cardiac events in contemporary cardiac CT trials such as SCOT-HEART [Scottish Computed Tomography of the HEART] and DISCHARGE [Diagnostic Imaging Strategies for Patients with Stable Chest Pain and Intermediate Risk of Coronary Artery Disease]).^{10,40} The 2024 guideline compared their prevalences to external CTA cohorts rather than to the current clinical gold standard of ICA for obstructive CAD as derived from the current paper. The 2024 guidelines did not include CT in their Risk Factor-weighted Clinical Likelihood model. Our analysis shows the added value of the PTP calculations even in the presence of CTA results, which advocates for the use of PTP. In clinical practice, despite patients having a low PTP, many patients

TABLE 3 Estimates of the Logistic Regression Models With Random Effects (N = 5,332)

	Estimate (SE)	P Value	OR (95% CI)
COME-CCT-PTP calculator			
Age (centered)	0.036 (0.003)	<0.001	1.04 (1.03-1.04)
Sex (male vs female)	0.986 (0.068)	<0.001	2.68 (2.35-3.06)
Symptoms ^a			
Typical angina	1.427 (0.118)	<0.001	4.17 (3.30-5.25)
Atypical angina	0.307 (0.117)	0.009	1.36 (1.08-1.71)
Nonanginal chest discomfort	0.119 (0.132)	0.365	1.13 (0.87-1.46)
Other chest discomfort	Reference group		1.00
Model constant	−1.434 (0.151)	—	—
Random intercept (τ^2) ^b	0.667 (0.816)		
BIC	6,398.43		
logLik	−3,169.18		
CTA			
CTA (obstructive vs nonobstructive CAD)	2.973 (0.078)	<0.001	19.55 (16.78-22.78)
Model constant	−1.893 (0.103)	—	—
Random intercept (τ^2) ^b	0.348 (0.590)		
BIC	5,061.43		
logLik	−2,517.84		
Combined COME-CCT-PTP calculator with CTA			
Age (centered)	0.030 (0.004)	<0.001	1.03 (1.02-1.04)
Sex (male vs female)	0.868 (0.081)	<0.001	2.38 (2.03-2.79)
Symptoms ^a			
Typical angina	1.346 (0.137)	<0.001	3.84 (2.94-5.03)
Atypical angina	0.195 (0.134)	0.146	1.22 (0.93-1.58)
Nonanginal chest discomfort	0.156 (0.154)	0.310	1.17 (0.86-1.58)
Other chest discomfort	Reference group		1.00
CT result (obstructive vs not obstructive)	2.924 (0.082)	<0.001	18.62 (15.86-21.86)
Model constant	−3.030 (0.159)	—	—
Random intercept (τ^2) ^b	0.377 (0.614)		
BIC	4,740.58		
logLik	−2,335.96		

^aTypical angina defined as retrosternal chest discomfort, precipitation by exertion, and prompt relief (within 30 s-10 min) by rest or nitroglycerin. Patients in whom 2, one, or none of these 3 criteria were found were classified as having atypical angina, nonanginal chest discomfort, and other chest discomfort, respectively. ^bVariance component estimate (τ^2) for random intercept. Please see [Supplemental Table 2](#) for the published coefficients of the updated Diamond-Forrester model. For the original Diamond-Forrester model we used the published look-up tables.³¹

BIC = Bayesian information criterion; other abbreviations as in [Tables 1 and 2](#).

may still and do undergo ICA with negative results.^{41,42} Our future analysis will apply the COME-CCT-PTP with CTA in the DISCHARGE trial cohort to provide external validation in a pragmatic cohort for such a proposed model.

The COME-CCT-PTP calculator model with CTA provides individual pretest and posttest probability assessment for clinical decision-making, for example, when posttest probability after negative CTA is low (<15% according to the European guideline), the patient should be evaluated for other underlying causes of chest pain. In patients with intermediate PTP of CAD, a positive CTA is likely to increase posttest probability, and ICA is recommended in high-risk anatomy CAD. The prediction model uses information routinely available during clinical evaluation

(age, sex, and chest pain characteristics) and thus may result in more frequent use⁴³ than more time-consuming approaches such as the Duke clinical score, which requires 9 patient characteristics for probability estimation.⁴⁴ Our COME-CCT-PTP calculator model combined with CTA is a pragmatic decision aid as recommended by American⁷ and European guidelines,²² aimed at improving physician-patient interactions by providing immediate evidence-based feedback on the probability of CAD according to the Salzburg statement.⁴⁵ Most importantly, the probabilities provided by the prediction model may facilitate better integration of disease probabilities and risks of complications with patients' preferences for subsequent testing⁴⁶ into shared decision-making processes.⁴⁷ This has potential to increase


CENTRAL ILLUSTRATION Combining Pretest Probability Calculator With Cardiac CT

Pretest Probability and Cardiac CT for Diagnosing Obstructive Coronary Artery Disease Were Combined in This Individual Patient Data-Derived Systematic Review

- Collaborative Meta-Analysis of Cardiac CT (COME-CCT) Consortium formulated a pretest probability model (PTP)
- 65 prospective diagnostic accuracy published studies retrieved and analyzed
- Only patients referred to invasive coronary angiography were included
- Data derived from Individual patient data only


4 models tested in mixed effects logistic regression:

- Traditional Diamond-Forrester model
- COME-CCT PTP model
- Cardiac CT model alone
- COME-CCT-PTP and cardiac CT model




Spaghetti Plot of Stratification of Patients With and Without Obstructive CAD
Best prediction was accomplished with the combination of COME-CCT-PTP calculator and CTA

A Typical Angina + Atypical Angina



— COME-CCT-PPT + CTA (AUC = 84.9%)
- - CTA Alone (AUC = 78.8%)
— COME-CCT-PPT (AUC = 89.5%)
— DICAD (AUC = 89.8%)
— Diamond Forrester (AUC = 68.2%)

B Nonanginal + Other Chest Discomfort



— COME-CCT-PPT + CTA (AUC = 87.6%)
- - CTA Alone (AUC = 84.7%)
— COME-CCT-PPT (AUC = 82.6%)
— DICAD (AUC = 63.1%)
— Diamond Forrester (AUC = 62.3%)

Discriminative Ability of Prediction Models Depending on Chest Pain Type
Combining the COME-CCT-PTP with cardiac CT gave the best discriminant prediction for obstructive CAD in all chest pain subtypes
Typical + atypical angina, AUC: 0.85, 95% CI: 0.84-0.86
Non-anginal + other chest discomfort, AUC: 0.88, 95% CI: 0.86-0.89

Wieske V, et al. JACC Adv. 2025;4(8):102014.

Abbreviations as in Figures 1 and 2.

cost-effectiveness and patient safety by reducing unnecessary testing.⁴⁸

The discriminative ability of pragmatic clinical prediction models decreases in patients with non-anginal or other chest discomfort when compared with patients presenting with typical or atypical angina pectoris. This is clinically important as more accurate prediction is needed in patients with less typical presentation because ambiguity about appropriate diagnostic testing and management is greatest in these patients with intermediate disease probability. About a third of the cohort in our analysis had nonanginal or other chest discomfort and in

this group the added value of CTA for improving the prediction was most evident. Including CTA with the PTP model, resulting in an AUC of 0.86, clearly improved differentiation of patients with stable chest pain and suspected CAD compared with PTP models alone. Winther et al recently showed that more patients were reclassified with low PTPs (<15%) using a large Danish chronic coronary syndrome cohort, of which 8,028 patients (19%) underwent both CTA and ICA correlation.⁴⁹ However, PTP models were not combined with CTA in that analysis, and instead CTA and ICA were used as a combined endpoint. Cheng et al studied a population of 14,048 patients clinically

referred for CTA, but not ICA, and showed that CAD prevalence was overestimated by three-fold (51% vs 18%) using the original Diamond-Forrester prediction model for estimating probabilities.⁵⁰ The better agreement in our study can be explained by a higher-risk population with 48.3% prevalence of CAD, and all patients had already been clinically referred for ICA. Hence, among lower-risk patients, such as the subgroup of nonanginal or other chest discomfort patients in our study and a recent single-center analysis of 2,274 patients referred for CT,⁵¹ clinical prediction alone becomes less accurate because it is being applied to populations from which the predictors were not derived. Importantly, the good discriminative ability of the COME-CCT-PTP calculator with CTA was similar in patients with typical or atypical angina and in patients with nonanginal or other chest discomfort. Including coronary calcium score by CT improves clinical prediction but was not included as discriminative ability and noncalcified plaque burden assessment is less compared with CTA.³⁹ We also decided against the inclusion of functional testing into the prediction model because of limited sensitivity when adjusted for referral bias.⁵² Indeed, Patel et al have recently shown that the diagnostic yield of ICA is highest if it is performed following CTA (around 70%) and is relevantly lower (around 45%) when following by any functional test.⁵³ In a smaller study of 527 patients with acute-onset chest pain, functional tests did not improve discriminative ability.⁵⁴ Since both CTA and functional tests showed advantages in the PROMISE (PROspective Multicenter Imaging Study for Evaluation of Chest Pain)⁵⁵ and SCOT-HEART trial,⁵⁶ it would be interesting to compare their value for refining disease risk estimations.

STUDY LIMITATIONS. Patients included in the COME-CCT Consortium had an indication for ICA, which was performed in all patients to avoid verification bias. The cohort thus represents a certain spectrum of patients with suspected CAD with a prevalence of obstructive CAD of 48.3% and only 33.3% of patients with nonanginal or other chest discomfort. Results may not be representative of lower-risk patients being considered for CTA.⁵⁷ Moreover, the reference standard ICA has considerable interobserver variability, although quantitative analysis of ICA was used in more than 70% of retrieved studies.⁵⁸ Invasive fractional flow reserve is an alternative reference standard for assessing the functional significance of anatomic lesions but was not consistently determined in retrieved studies. CT perfusion⁵⁹ and CT fractional flow reserve⁶⁰ are recent tools for quantitative assessment of

myocardial ischemia,⁶¹ but not yet widely available in clinical practice. As commonly observed in individual patient data meta-analyses,⁶² only 49% of individual patient data could be obtained from all original studies. Moreover, meta-analyses with inclusion of more than 50 original studies, such as ours, are rare and more difficult to conduct.⁶² Non-diagnostic CTA results were included in the model using 2-by-3 tables²³ as a sensitivity analysis and showed slightly reduced discriminative ability especially in patients with typical or atypical angina. The clinical prediction including CTA showed clinical net benefit in the decision curve analysis and good predictive performance with good discriminative ability and acceptable calibration. The internal-external cross-validation showed acceptable results. Future work should focus in large cohort trials on validating a combined PTP and CTA approach to optimize patient management and treatment.

CONCLUSIONS

Our collaborative analysis of individual patient data shows the potential for combining clinical PTP assessments with CTA, which may result in improved clinical decision-making in patients with suspected CAD.

ACKNOWLEDGMENTS The authors thank all members of the COME-CCT Consortium who contributed to this analysis. The COME-CCT Consortium writing committee members, contributions, collaborators, and members of the steering committee, data management team, and coordinating center are listed in the [Supplemental Appendix](#).

FUNDING SUPPORT AND AUTHOR DISCLOSURES

The COME-CCT Consortium is funded by a joint program of the German Research Foundation and the German Federal Ministry of Education and Research (01KG1110) and the Digital Health Accelerator of the Berlin Institute of Health to Dr Dewey. All researchers are independent of the funding bodies. The funding bodies had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the manuscript for publication. Dr Wieske has received grant support from the FP7 Program of the European Commission for the randomized multicenter DISCHARGE trial (603266-2, HEALTH-2012.2.4.-2). Dr Pontone has received other grants from General Electric, grants from General Electric, other from Medtronic, other from Bracco, outside the submitted work. Dr Hoe is on the Speakers Bureau for Abbott Vascular and Edwards Lifesciences. Dr Gerber reports that the Cliniques St Luc UCL holds a master research agreement with Philips Medical Systems. Dr Schoepf has received institutional grants, personal fees, and nonfinancial support from Astellas, Bayer, General Electric, Guerbet, HeartFlow, and Siemens. Dr Nørgaard has received grants from Siemens and HeartFlow. AS has received personal fees from General Electric and Toshiba. Dr Knuuti has received grants from CardiRad and personal fees from GE Healthcare. Dr Buechel reports that the University

Hospital Zurich holds a research contract with GE Healthcare. Dr Nikolaou reports collaborations with and project funding from Siemens Healthineers, Bayer Healthcare, GE Healthcare, and Speakers Bureau: Siemens Healthineers, Bayer Healthcare. Dr Chen has received an institutional research agreement with Canon Medical, formerly Toshiba Medical (no financial support/funding). Dr Halon has received other grant from Philips Healthcare, Cleveland, Ohio, during the conduct of the primary study. Dr Chow holds the Saul and Edna Goldfarb Chair in Cardiac Imaging Research; has received research support from GE Healthcare and educational support from TeraRecon Inc during the conduct of the study. Dr Kaufmann reports that the University Hospital Zurich holds a research agreement with GE Healthcare. Dr Arbab-Zadeh has received grant support from Canon Medical Systems. Dr Paul is on the Speakers Bureau for Toshiba Medical Systems; and has received grants from Toshiba Medical Systems, outside the submitted work. Dr Schuetz has received grants support for his salary from German Federal Ministry of Education and Research (BMBF) during the conduct of the study. Dr Dewey has received grant support from the FP7 Program of the European Commission for the randomized multicenter DISCHARGE trial (603266-2, HEALTH-2012.2.4.-2); also has received grant support from German Research Foundation (DFG) in the Heisenberg Program (DE 1361/14-1), graduate program on quantitative biomedical imaging (BIOQIC, GRK 2260/1), for fractal analysis of myocardial perfusion (DE 1361/18-1), the Priority Programme Radiomics for the investigation of coronary plaque and coronary flow (DE 1361/19-1 [428222922] and 20-1 [428223139] in SPP 2177/1); and also received funding from the Berlin University Alliance (GC_SC_PC 27) and from the Digital Health Accelerator of the Berlin Institute of Health. Dr Dewey has received lecture fees from Canon, Guerbet. Prof Dodd has received grant support from the Irish Lung Foundation, the St. Vincent's Hospital Group Foundation, University College Dublin, and the FP7 Program of the European Commission for the randomized multicenter DISCHARGE trial (603266-2, HEALTH-2012.2.4.-2); is an associate editor of *Radiology*, *Respirology*, and the *Quarterly Journal of Medicine*; is an Editorial Board member of *Radiology Cardiothoracic Imaging*; and is an author in the Stat-Dx book Series Diagnostic Imaging - Cardiovascular and the textbook CT and MRI in Cardiology, Elsevier and the opinions expressed in this article are the author's own and do not represent the view of ESR. Per the guiding principles of ESR, the

work as Research Chair is on a voluntary basis and only remuneration of travel expenses occurs. Dr Dewey is also the editor of *Cardiac CT*, published by Springer Nature, and offers hands-on courses on CT imaging (www.ct-kurs.de). Institutional master research agreements exist with Siemens, General Electric, Philips, and Canon. The terms of these arrangements are managed by the legal department of Charité-Universitätsmedizin Berlin. Dr Dewey holds a joint patent with Florian Michalek on dynamic perfusion analysis using fractal analysis (PCT/EP2016/071551). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

ADDRESS FOR CORRESPONDENCE: Dr Jonathan D. Dodd, Department of Radiology, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland. E-mail: jonniedodd@gmail.com.

PERSPECTIVES

COMPETENCY IN MEDICAL KNOWLEDGE:

Pragmatic clinical prediction models have a poor discriminative ability to predict obstructive CAD, particularly in patients with nonanginal or other chest discomfort. Incorporating cardiac CT results into such models may significantly improve the differentiation of patients with stable chest pain and obstructive disease.

TRANSLATIONAL OUTLOOK:

Adding cardiac CTA to clinical prediction models may improve their discriminative ability in detecting patients with obstructive CAD and should be evaluated in future validation trial cohorts.

REFERENCES

- Mensah GA, Fuster V, Murray CJL, Roth GA. Global burden of cardiovascular diseases and risks, 1990-2022. *J Am Coll Cardiol*. 2023;82:2350-2473.
- Lampe FC, Morris RW, Walker M, Shaper AG, Whincup PH. Trends in rates of different forms of diagnosed coronary heart disease, 1978 to 2000: prospective, population based study of British men. *BMJ*. 2005;330:1046.
- George J, Rapsomaniki E, Pujades-Rodriguez M, et al. How does cardiovascular disease first present in women and men? Incidence of 12 cardiovascular diseases in a contemporary cohort of 1,937,360 people. *Circulation*. 2015;132:1320-1328.
- Hemingway H, McCallum A, Shipley M, Manderbacka K, Martikainen P, Keskimäki I. Incidence and prognostic implications of stable angina pectoris among women and men. *JAMA*. 2006;295:1404-1411.
- Buckley B, Murphy AW. Do patients with angina alone have a more benign prognosis than patients with a history of acute myocardial infarction, revascularisation or both? Findings from a community cohort study. *Heart*. 2009;95:461-467.
- Russell M, Williams M, May E, Stewart S. The conundrum of detecting stable angina pectoris in the community setting. *Nat Rev Cardiol*. 2010;7:106-113.
- Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American college of Cardiology/American heart association joint committee on clinical practice guidelines. *Circulation*. 2021;144:e368-e454.
- Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. *Eur Heart J*. 2024;45:3415-3537.
- Juarez-Orozco LE, Saraste A, Capodanno D, et al. Impact of a decreasing pre-test probability on the performance of diagnostic tests for coronary artery disease. *Eur Heart J Cardiovasc Imag*. 2019;20:1198-1207.
- Maurovich-Horvat P, Bosserdt M, Kofoed KF, et al. DISCHARGE trial group. CT or invasive coronary angiography in stable chest pain. *N Engl J Med*. 2022;386:1591-1602.
- Schuetz GM, Schlattmann P, Achenbach S, et al. Individual patient data meta-analysis for the clinical assessment of coronary computed tomography angiography: protocol of the Collaborative meta-analysis of Cardiac CT (CoMe-CCT). *Systematic Rev*. 2013;2:13.
- Haase R, Schlattmann P, Gueret P, et al. Diagnosis of obstructive coronary artery disease using computed tomography angiography in patients with stable chest pain depending on clinical probability and in clinically important subgroups: meta-analysis of individual patient data. *BMJ*. 2019;365:l1945.
- Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. *Ann Intern Med*. 2015;162:W1-W73.

14. Debray TP, Riley RD, Rovers MM, Reitsma JB, Moons KG. Individual participant data (IPD) meta-analyses of diagnostic and prognostic modeling studies: guidance on their use. *PLoS Med*. 2015;12:e1001886.
15. Schueler S, Walther S, Schuetz GM, Schlattmann P, Dewey M. Methodological quality of diagnostic accuracy studies on non-invasive coronary CT angiography: influence of QUADAS (Quality Assessment of Diagnostic Accuracy Studies included in systematic reviews) items on sensitivity and specificity. *Eur Radiol*. 2013;23:1603-1622.
16. Walther S, Schueler S, Tackmann R, Schuetz GM, Schlattmann P, Dewey M. Compliance with STARD checklist among studies of coronary CT angiography: systematic review. *Radiol*. 2014;271:74-86.
17. Wasson JH, Sox HC, Neff RK, Goldman L. Clinical prediction rules. Applications and methodological standards. *N Engl J Med*. 1985;313:793-799.
18. Brown H, Prescott R. *Applied Mixed Models in Medicine*. John Wiley & Sons, Ltd; 2015.
19. Diamond GA. A clinically relevant classification of chest discomfort. *J Am Coll Cardiol*. 1983;1:574-575.
20. Diamond GA, Forrester JS, Hirsch M, et al. Application of conditional probability analysis to the clinical diagnosis of coronary artery disease. *J Clin Invest*. 1980;65:1210-1221.
21. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J*. 2013;34:2949-3003.
22. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J*. 2020;41:407-477.
23. Schuetz GM, Schlattmann P, Dewey M. Use of 3x2 tables with an intention to diagnose approach to assess clinical performance of diagnostic tests: meta-analytical evaluation of coronary CT angiography studies. *BMJ*. 2012;345:e6717.
24. Skrondal A, Rabe-Hesketh S. Prediction in multilevel generalized linear models. *J R Statist Soc A*. 2009;172:659-687.
25. Debray TP, Moons KG, Ahmed I, Koffijberg H, Riley RD. A framework for developing, implementing, and evaluating clinical prediction models in an individual participant data meta-analysis. *Stat Med*. 2013;32:3158-3180.
26. Steyerberg EW. *Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating*. New York: Springer; 2009.
27. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiol*. 1982;143:29-36.
28. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. *Med Decis Making*. 2006;26:565-574.
29. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Stat Med*. 1996;15:361-387.
30. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for some traditional and novel measures. *Epidemiol*. 2010;21:128-138.
31. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. *N Engl J Med*. 1979;300:1350-1358.
32. Genders TS, Steyerberg EW, Alkadhi H, et al. A clinical prediction rule for the diagnosis of coronary artery disease: validation, updating, and extension. *Eur Heart J*. 2011;32:1316-1330.
33. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7:177-188.
34. R Core Team. *R: A language and environment for statistical computing*. Vienna, Austria: R Foundation for Statistical Computing; 2014.
35. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. *J Stat Softw*. 2015;1(1):2015.
36. Kundu S, Aulchenko YS, van Duijn CM, Janssens AC. PredictABEL: an R package for the assessment of risk prediction models. *Eur J Epidemiol*. 2011;26:261-264.
37. Schwarzer G. *meta: meta-Analysis with R. R package version 3.2-1*. 2014.
38. Vale CL, Rydzewska LH, Rovers MM, et al. Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study. *BMJ*. 2015;350:h1088.
39. Genders TS, Steyerberg EW, Hunink MG, et al. Prediction model to estimate presence of coronary artery disease: retrospective pooled analysis of existing cohorts. *BMJ*. 2012;344:e3485.
40. Newby DE, Adamson PD, Berry C, et al. SCOT-HEART investigators. Coronary CT angiography and 5-year risk of myocardial infarction. *N Engl J Med*. 2018;379:924-933.
41. Bradley SM, Maddox TM, Stanislawski MA, et al. Normal coronary rates for elective angiography in the veterans affairs Healthcare system: insights from the VA CART program (veterans affairs clinical assessment reporting and tracking). *J Am Col Cardiol*. 2014;63:417-426.
42. Patel MR, Peterson ED, Dai D, et al. Low diagnostic yield of elective coronary angiography. *N Engl J Med*. 2010;362:886-895.
43. Noble D, Mathur R, Dent T, Meads C, Greenhalgh T. Risk models and scores for type 2 diabetes: systematic review. *BMJ*. 2011;343:d7163.
44. Pryor DB, Shaw L, McCants CB, et al. Value of the history and physical in identifying patients at increased risk for coronary artery disease. *Ann Intern Med*. 1993;118:81-90.
45. Salzburg Global Seminar. Salzburg statement on shared decision making. *BMJ*. 2011;342:d1745.
46. Schönenberger E, Schnapauff D, Teige F, Laule M, Hamm B, Dewey M. Patient acceptance of noninvasive and invasive coronary angiography. *PLoS One*. 2007;2:e246.
47. Agoritsas T, Heen AF, Brandt L, et al. Decision aids that really promote shared decision making: the pace quickens. *BMJ*. 2015;350:g7624.
48. Hurley R. Can doctors reduce harmful medical overuse worldwide? *BMJ*. 2014;349:g4289.
49. Winther S, Schmidt SE, Rasmussen LD, et al. Validation of the European Society of Cardiology pre-test probability model for obstructive coronary artery disease. *Eur Heart J*. 2021;42:1401-1411.
50. Cheng VY, Berman DS, Rozanski A, et al. Performance of the traditional age, sex, and angina typicality-based approach for estimating pretest probability of angiographically significant coronary artery disease in patients undergoing coronary computed tomographic angiography: results from the multinational coronary CT angiography evaluation for clinical outcomes: an international multicenter registry (CONFIRM). *Circulation*. 2011;124:2423-2432.
51. Bittencourt MS, Hultén E, Polonsky TS, et al. European society of cardiology-recommended coronary artery disease consortium pretest probability scores more accurately predict obstructive coronary disease and cardiovascular events than the Diamond and forrester score: the partners registry. *Circulation*. 2016;134:201-211.
52. Ladapo JA, Blecker S, Elashoff MR, et al. Clinical implications of referral bias in the diagnostic performance of exercise testing for coronary artery disease. *J Am Heart Ass*. 2013;2:e000505.
53. Patel MR, Dai D, Hernandez AF, et al. Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice. *Am Heart J*. 2014;167:846-852.e2.
54. Sogaard M, Linde JJ, Kofoed KF, et al. Diagnostic value of the updated Diamond and forrester score to predict coronary artery disease in patients with acute-onset chest pain. *Cardiol*. 2016;133:10-17.
55. Douglas PS, Hoffmann U, Patel MR, et al. Outcomes of anatomical versus functional testing for coronary artery disease. *N Engl J Med*. 2015;372:1291-1300.
56. Scot-Heart investigators. CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trial. *Lancet*. 2015;385:2383-2391.
57. Arbab-Zadeh A, Miller JM, Rochitte CE, et al. Diagnostic accuracy of computed tomography coronary angiography according to pre-test probability of coronary artery disease and severity of coronary arterial calcification. The CORE-64 (Coronary Artery Evaluation Using 64-Row Multidetector Computed Tomography Angiography) International multicenter study. *J Am Col Cardiol*. 2012;59:379-387.

58. Zir LM, Miller SW, Dinsmore RE, Gilbert JP, Harthorne JW. Interobserver variability in coronary angiography. *Circulation*. 1976;53:627-632.

59. Rochitte CE, George RT, Chen MY, et al. Computed tomography angiography and perfusion to assess coronary artery stenosis causing perfusion defects by single photon emission computed tomography: the CORE320 study. *Eur Heart J*. 2014;35:1120-1130.

60. Douglas PS, Pontone G, Hlatky MA, et al. Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided

diagnostic strategies vs. usual care in patients with suspected coronary artery disease: the prospective longitudinal trial of FFRCT: outcome and resource impacts study. *Eur Heart J*. 2015;36:3359-3367.

61. Dewey M, Siebes M, Kachelriess M, et al. Clinical quantitative cardiac imaging for the assessment of myocardial ischaemia. *Nat Rev Cardiol*. 2020;17:427-450.

62. Ahmed I, Sutton AJ, Riley RD. Assessment of publication bias, selection bias, and unavailable data in meta-analyses using individual

participant data: a database survey. *BMJ*. 2012;344:d7762.

KEY WORDS computed tomography angiography, coronary artery disease, disease probability, individual patient data meta-analysis, stable chest pain

APPENDIX For supplemental information, tables, and figures, please see the online version of this paper.